| Identification | Back Directory | [Name]
11-Hexadecenoic acid, 16-[[(ethylaMino)carbonyl]aMino]-, (11Z)- | [CAS]
1184844-74-3 | [Synonyms]
CAY10662
CAY10662 Exclusive
OUFBVXMGWWCVFO-CLFYSBASSA-N
11-Hexadecenoic acid, 16-[[(ethylaMino)carbonyl]aMino]-, (11Z)- | [Molecular Formula]
C19H36N2O3 | [MOL File]
1184844-74-3.mol | [Molecular Weight]
340.5 |
| Chemical Properties | Back Directory | [Melting point ]
83.1-83.3 °C | [Boiling point ]
546.9±33.0 °C(Predicted) | [density ]
0.986±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 5 mg/ml; DMF:PBS (pH 7.2) (1:4): 0.2 mg/ml; DMSO: 3 mg/ml; Ethanol: 2 mg/ml | [pka]
4.78±0.10(Predicted) |
| Hazard Information | Back Directory | [Description]
17(R),18(S)-Epoxyeicosatetraenoic acid (17(R),18(S)-EpETE), a natural cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid, is known to reduce the contraction rate of spontaneously beating heart cells and to protect neonatal rat cardiomyocytes against arrhythmias induced by β-adrenergic agonists (EC50 = ~ 1-2 nM).1 CAY10662 is a 1,3 disubstituted urea derivative of 17(R),18(S)-EpETE that is more metabolically robust and reduces the contractility of cardiomyocytes with improved potency (EC50 < 1 nM) over its parent compound.1 At concentrations 1,000-fold higher than required for the effect on cardiomyocytes, 1-5 μM CAY10662 exerts weak dose-dependent soluble epoxide hydrolase inhibition.1 | [Uses]
(Z)-16-(Ethylcarbamoylamino)hexadec-11-enoic acid (Compound 21) is a vasorelaxant (EC50=5.7 μM) that can be used in cardiovascular disease research[1]. | [References]
1. Falck, J.R., Wallukat, G., Puli, N., et al. 17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analogues J. Med. Chem. 54(12),4109-4118(2011). |
|
|